Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

BioAtla (BCAB) EBIT Margin (2020 - 2025)

BioAtla's EBIT Margin history spans 4 years, with the latest figure at 462.75% for Q4 2025.

  • For Q4 2025, EBIT Margin changed N/A year-over-year to 462.75%; the TTM value through Dec 2025 reached 2965.25%, down 229304.0%, while the annual FY2025 figure was 2965.25%, 229304.0% down from the prior year.
  • EBIT Margin reached 462.75% in Q4 2025 per BCAB's latest filing, down from 102.45% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 102.45% in Q3 2024 to a low of 12184.0% in Q2 2021.
  • Average EBIT Margin over 3 years is 4249.73%, with a median of 462.75% recorded in 2025.
  • The largest YoY upside for EBIT Margin was -980505bps in 2021 against a maximum downside of -980505bps in 2021.
  • A 3-year view of EBIT Margin shows it stood at 12184.0% in 2021, then surged by 99bps to 102.45% in 2024, then crashed by -352bps to 462.75% in 2025.
  • Per Business Quant, the three most recent readings for BCAB's EBIT Margin are 462.75% (Q4 2025), 102.45% (Q3 2024), and 12184.0% (Q2 2021).